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Abstract
Objective: To identify causative mutations in a patient affected by ataxia and
spastic paraplegia. Methods: Whole-exome sequencing (WES) and whole-gen-
ome sequencing (WGS) were performed using patient’s DNA sample. RT-PCR
and cDNA Sanger sequencing were performed on RNA extracted from patient’s
fibroblasts, as well as western blot. Results: A novel missense variant in SPG7
(c.2195T> C; p.Leu732Pro) was first found by whole-exome sequencing (WES),
while the second, also unreported, deep intronic variant (c.286 + 853A>G) was
identified by whole-genome sequencing (WGS). RT-PCR confirmed the in silico
predictions showing that this variant activated a cryptic splice site, inducing the
inclusion of a pseudoexon into the mRNA sequence, which encoded a prema-
ture stop codon. Western blot showed decreased SPG7 levels in patient’s fibrob-
lasts. Interpretation: Identification of a deep intronic variant in SPG7, which
could only have been detected by performing WGS, led to a diagnosis in this
HSP patient. This case challenges the notion of an autosomal dominant inheri-
tance for SPG7, and illustrates the importance of performing WGS subsequently
or alternatively to WES to find additional mutations, especially in patients carry-
ing one variant in a gene causing a predominantly autosomal recessive disease.
Introduction
Hereditary spastic paraplegias (HSPs) are a group of
neurodegenerative diseases characterized by progressive
loss of upper motor neuron function. The primary
pathophysiological feature of the disease is a “dying back
type” axonal neuropathy that primarily affects upper
motor neurons of the pyramidal tract.1,2 Collectively,
more than 80 genes and at least 76 linkage loci have
been associated with HSP.3,4 Among all of these genes,
mutations in SPAST, ATL1, SPG7, and SPG11 remain
the most prevalent causes of HSP. Novel sequencing
strategies such as whole-exome sequencing (WES) have
accelerated the identification of causative variants associ-
ated with HSP, including the identification of novel
gene–disease associations,5 although the diagnostic rate
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reaches only ~ 50% in carefully selected cohorts of
patients.6,7 Whole-genome sequencing (WGS) can
improve the detection of variants, as it provides uniform
coverage of exonic regions (especially important to
screen regions that are not efficiently probed by WES),
the possibility of detecting deep intronic/intergenic vari-
ants, and improved calling of structural variants.8
Although WGS has a higher economic cost compared to
WES and the interpretation of non-coding variants
remains a challenge, it has already been used successfully
to find pathogenic variants in HSP patients and other
related neurological conditions (Table S1). In this report,
we describe a patient in which a missense heterozygous
variant in SPG7 was first found by WES. To find addi-
tional mutations, we performed WGS, which identified a
second heterozygous deep intronic variant in SPG7 that
could not have been detected by WES alone. After func-
tional analysis, we concluded that this second deep




The proband was recruited and examined at the Neurol-
ogy department of Donostia University Hospital. Detailed
neurological examinations were performed on all mem-
bers of the family. Blood samples and skin-derived fibrob-
last cell lines were obtained using standard methods.
Informed consent was obtained from all participants in
this study. The research project was approved by the
Clinical Research Ethics Committee for Research Ethics
Committee of the Bellvitge University Hospital (PR076/
14).
Whole-Exome (WES) and Whole-Genome
Sequencing (WGS)
Genomic DNA was extracted from peripheral blood
using standard methods. WES was performed on
patient’s DNA sample using the SureSelect XT Human
All Exon V5 50 Mb kit (Agilent) for DNA capture.
Exome and Genome DNA sequencing was performed
using the HiSeq 2000 Platform (Illumina) at CNAG
(Centre Nacional d’Analisi Genomica, Barcelona). Vari-
ants were filtered using RD-Cat platform (https://rdcat.c
nag.crg.eu/) and an in-house pipeline based on GATK
best practice guidelines and prioritization based on accu-
rate patient characterization with HPO terms (Human
Phenotype Ontology), interaction networks at physical
and functional levels and variant intolerance scores gen-
erated by the ExAC and gnomAD consortia. We
prioritized variants in HSP genes that had a frequency
lower than 0.01 in ExAC (Exome Aggregation Consor-
tium), 1000 genomes, ESP (NHLBI Exome Sequencing
Project), and gnomAD control databases. In silico predic-
tors were used to assess the effect of variants on splicing
(Human Splicing Finder, MaxEntScan, NNSplice, Net-
Gene2, FSplice, and SpliceAI9). Furthermore, we screened
a curated list of HSP (79), spinocerebellar ataxia (49),
and spastic ataxia genes (7). Candidate variants were val-
idated and tested for cosegregation in all family members
by Sanger sequencing.
RNA splicing analysis
Fibroblast cell lines from the proband, a healthy brother,
and an unrelated control were cultured at 37C and 5%
CO2 in Dulbecco’s modified eagle medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS) and 100U/
mL penicillin + 100µl/mL streptomycin. RNA was
extracted using the RNeasy Mini Kit (QIAGEN) and
cDNA was synthesized using the Superscript IV kit (Life
Technologies) following manufacturer’s instructions.
cDNA was amplified by polymerase chain reaction (PCR)
using primers targeting exons 1–4 of SPG7 gene (forward:
50-CGGCTTTCAGGCCAACAT-30; reverse: 50-CGCTCTC
GGTACATCTGGTC-30) followed by Sanger sequencing.
Western blot
For western blotting analyses, fibroblasts were homoge-
nized in RIPA buffer (150 mmol/L NaCl, 1% Nonidet
P40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mmol/L
Tris, pH 8.0), sonicated for 2 min at 4C, centrifuged,
mixed with 4X NuPAGE LDS Sample Buffer (Invitrogen)
and heated at 70C for 10 min. 60 µg of protein samples
was subjected to polyacrylamide gel electrophoresis at
120V in NuPAGE MOPS SDS Running Buffer (Invitro-
gen) supplemented with 5 mmol/L sodium bisulfite (Ref.
243973, Sigma-Aldrich). Proteins were transferred to
nitrocellulose membranes using iBlot 2 Gel Transfer
Device (Invitrogen). After blocking in 5% Bovine Serum
Albumin (BSA, Sigma-Aldrich), 0.05% TBS-Tween (TBS-
T) for 1 h at room temperature, membranes were incu-
bated with primary antibodies overnight at 4°C. Primary
antibodies included Anti-b-Actin, mouse (dilution 1/
8000, ref:A2228, Sigma-Aldrich); Anti-OPA1, mouse (di-
lution 1/1000, ref: 612607, BD Transduction Laborato-
ries); and Anti-SPG7, mouse (dilution: 1/500, ref: SC-
514393, Santa Cruz Biotechnology). After incubation with
secondary antibodies for 1 h at room temperature, pro-
teins were detected with ChemidocTM Touch Imaging
System (BioRad). Bands were quantified with ImageLab
(BioRad).
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Results
Clinical description
The proband (patient II.1) is a 52-year-old man in ongo-
ing follow-up at the neurology outpatient clinic of
Donostia University Hospital due to a 15-year-long his-
tory of altered gait. Spastic paraplegia with gait ataxia was
observed at the first examination in 2005. Mild progres-
sive external ophthalmoplegia (PEO) with ptosis and
cerebellar dysarthria were also present. This patient is the
first of three sons of a non-consanguineous couple of
Spanish origin. His father had suffered from a paraneo-
plastic anti-Hu-positive cerebellar and polyneuropathic
ataxia associated with small-cell lung cancer and recently
died at the age of 73 years. There are no other family
members suffering from any disease affecting the central
or peripheral nervous system.
A complete diagnostic workup was undertaken to
exclude any acquired cause of spastic paraparesis or gait
ataxia. Full blood analysis was normal, including absence
of acanthocytosis, and negative antineuronal, onconeu-
ronal, and ganglioside antibodies. Only antinuclear anti-
bodies were positive in 1/640 titers for several analyses,
but a thorough rheumatology study was unremarkable,
including negative autoantibodies and normal salivary
gland biopsy. Oxysterol levels ruled out Niemann Pick
disease. CSF analysis was also unremarkable. On MRI,
there was bilateral frontotemporal and right parietal atro-
phy with grade 1 subcortical leukoencephalopathy. No T2
hyperintensities were seen in the dentate nuclei. There
was concomitant cerebellar atrophy and no signs of
myelopathy (Fig. 1A and B). Whole-body muscle-MRI
showed no myopathic changes, and thoracoab-
dominopelvic CT scan was negative for any mass sugges-
tive of malignancy. There was no evidence of
polyneuropathy or myopathy on nerve conduction studies
and electromyography. Genetic analysis for different
spinocerebellar ataxias (SCA1, 2, 3, 6, 7), DRPLA and
Friedreich ataxia were negative. Furthermore, no muta-
tions were found in the mitochondrial DNA.
The patient’s disability has progressed slowly, and at the
last visit (May 2019), he is currently able to walk short dis-
tances with a walker or cane, requiring a wheelchair for the
rest of activities. The Spastic Paraplegia Rating Scale (SPRS)
was 15/52 (1,3,2,2,2,2,1,1,1,0,0,0,0), the timed 25-foot walk
test (T25FW) was 15.94 sec, and the 6-min walk test
(6MWT) was 177 meters. No waddling or signs of proximal
myopathy were observed. There has been no cognitive or
behavioral decline up to this date. He continues to show cere-
bellar dysarthria. A slight improvement was observed after
1 month of fampridine (Fampyra) (T25FW = 13.73 sec),
while other symptomatic treatments failed.
Molecular studies
WES analysis identified a heterozygous missense variant
in SPG7 (chr16:89623308T> C hg19, NM_003119.3:
c.2195T> C, p.Leu732Pro), which was inherited from his
father (Fig. 1C). This variant is completely absent from
control databases, is highly conserved in evolution (GERP
score: 5.59), is predicted to be deleterious by at least three
different predictors (PolyPhen-2, SIFT, MutationTaster),
and is located in the conserved peptidase M41 domain,
close to other described missense mutations. Based on
these data, we classified the variant as “Likely Pathogenic”
according to ACMG/AMP guidelines.10 As the clinical
presentation of this patient was compatible with muta-
tions in SPG7, and as we did not find other rare candi-
date variants in exome data for this patient, we decided
to perform WGS on this patient’s sample to seek a second
variant in SPG7, while using better coverage to rule out
other possible disease-causative genes or novel candidates
that could underlie our patient’s phenotype.
Indeed, while WGS did not detect candidate variants of
interest in other HSP or ataxia genes, it revealed a novel
heterozygous variant within intron 2 of the SPG7 gene,
which was inherited from the mother (Fig. 1C). This vari-
ant (chr16:89577853A> G hg19, NM_003119.3:
c.286 + 853A>G) is deep intronic (>100 bp from the
splice site), completely absent from control databases, and
has not been previously reported as associated with dis-
ease. Segregation in two healthy siblings was compatible
with pathogenicity of the variant. In silico analysis using
various splice site predictors suggested the activation of a
cryptic donor site 5 bp upstream from this variant
(Table S2). Furthermore, SpliceAI, a very novel tool to
predict cryptic splice sites based on deep learning of arti-
ficial neural networks,9 additionally predicted the activa-
tion of an acceptor site located 80 bp upstream from the
c.286 + 853A>G variant at c.286 + 773. This novel accep-
tor site should function in conjunction with the previous
donor site of exon 2 at position c.286 + 1, leading to the
inclusion of a cryptic exon from c.286 + 774 to
c.286 + 848. The effect appeared specific for the change
c.286 + 853A>G, as no donor or acceptor activation
events were predicted by SpliceAI for other nucleotide
changes, such as c.286 + 853 A> C or A> T. Thus, we set
out to validate the prediction and extracted cDNA from
the patient’s fibroblasts, a healthy sibling, and an addi-
tional control. Gel analysis and Sanger sequencing
revealed that a 75 bp in-frame pseudoexon was retained
in the cDNA as a consequence of the c.286 + 853A>G
variant, matching the SpliceAI prediction (Fig. 1D). This
novel mRNA species contains an immediate, premature
stop codon at p.(Gly96Gly*1), which is supposed to
induce degradation of the transcript by nonsense
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mediated decay (NMD) (Fig. 1E). No evidence of tran-
scripts containing this pseudoexon was found in the
RNA-seq data of control fibroblasts from the Genotype-
Tissue Expression project (GTEx, https://gtexportal.org).
Ensuing this functional validation, the c.286 + 853A>G
variant can be classified as “Pathogenic” according to
ACMG/AMP guidelines.10 Western blot analyses showed
that SPG7 protein was firmly decreased in patient II.1
fibroblasts compared to controls, in concordance with the
expected loss-of-function effect of the deep intronic vari-
ant, while his healthy brother showed a less severe reduc-
tion in SPG7 levels, possibly linked to an effect of the
p.Leu732Pro variant on protein stability (Fig. 1F). On the
other hand, OPA1 protein levels were strongly upregu-
lated in patient II.1, a feature that has also been observed
in other SPG7-mutated patients.11 Thus, protein analysis
further confirmed the implication of SPG7 variants on
our patient’s phenotype.
Discussion
In this work, we present a case in which WGS was indis-
pensable to identify the causative mutations in an HSP
patient. Although various studies in the last years have
used WGS to study the etiology of HSP, the variants
identified in these works were located near or inside
coding regions and could very probably have been
detected by WES (Table S1). In contrast, our patient
harbored a deep intronic variant inducing the inclusion
of a pseudoexon and premature stop sites, which could
not have been identified with WES alone, underscoring
the usefulness of WGS to increase diagnostic yield. Alter-
natively, transcriptome sequencing could have been used,
as it has recently been proven useful for other genetic
diseases.12,13 Deep intronic mutations are estimated to
account for 10% of pathogenic mutations in the general
rare genetic disorders population,9,14 and could underlie
a significant number of undiagnosed HSP/ataxia cases as
it has been shown in our case,15,16 although it is still
underreported.
This case, in which only one coding variant was
detected at first, highlights that the existence of dominant
variants in SPG7 should be reexamined. To date, the
main argument supporting a dominant inheritance of
some variants is the description of four families with
patients with two mutations having an affected relative
carrying only one mutated allele and confirmed by Sanger
sequencing.17–19 Moreover, at least 10 apparently domi-
nant HSP families have been reported, in which the par-
ents of index patients with two mutations in trans were
also affected, although their carrier status was not con-
firmed by Sanger sequencing.20 However, a full screening
of SPG7 in heterozygous affected relatives was not under-
taken in any of these works. It is tempting to speculate
that some heterozygous patients in these families in fact
carry a third pathogenic allele that would have eluded
identification in a first screening, thus mimicking a domi-
nant or pseudodominance pattern in the first instance.
Indeed, three families with a pseudodominant mode of
inheritance have already been described, with three differ-
ent pathogenic alleles segregating in the family.21,22 It is
worth noting that the p.Ala510Val pathogenic variant is
relatively frequent in public control databases (0.25% in
ExAC, 0.4% in European population) and was carried in
homozygotes by some affected individuals in the three
families mentioned. Although the pseudodominance sce-
nario would not reconcile well with the existence of
SPG7-mutated families with three affected generations
described in literature, we believe that full gene screening
in the apparently heterozygous individuals should be
required for claiming the existence of dominant muta-
tions in SPG7 in future cases, including non-coding
regions undetectable by WES. As suggested by this case
description, WGS and cDNA/transcriptome sequencing
will become key diagnostic tools for uncovering muta-
tions undetectable by WES. In addition, these techniques
Figure 1. MRI brain images and functional evaluation in fibroblasts from Patient II.1. (A, B) Brain MRI of subject II.1 showing typical cerebellar
atrophy of SPG7 disease (sagittal T2w) (A), and bilateral frontotemporal and right parietal atrophy with grade 1 subcortical leukoencephalopathy
(coronal FLAIR) (B). (C) Family pedigree and genotype data for the SPG7 variants. Symbols: square, male; circle, female; filled, affected individual;
half-filled, clinically healthy carriers; asterisk, individual sequenced by WES/WGS. Variants found in SPG7 are shown below each symbol. WT: wild-
type. (D) Agarose gel electrophoresis of RT-PCR products showing an additional fragment (513 bp) in patient II.1. No products were observed in
negative RT controls or water controls (blank). A healthy family member (II.2) not carrying the c.286 + 853A>G variant and an unrelated
individual were used as healthy controls. (E) Consequence of the c. 286 + 853 A> G variant. WT: structure of wild-type SPG7 transcript (exons 1–
4). MUT: structure of SPG7 transcript generated by the c. 286 + 853 A> G variant. The pseudoexon results from a cryptic donor splice site
activation upstream from the c.286 + 853A>G mutation. The in-frame inclusion of 75 nucleotides of intron 2 (blue, pseudoexon ᴪ2b) translates
into premature stop codons at positions 1 and 4 downstream. Arrows indicate primers used for RT-PCR. cDNA Sanger sequencing shows two
populations of mRNA, one corresponding to pseudoexon inclusion and the other to exon 3. (F) Western blot of OPA1 and SPG7 proteins for
human fibroblasts of individuals II.1 (patient), II.2 (healthy brother) and controls (n = 3). Right, quantification of western blot bands. Data
represented as mean  SD
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could also help to assess the pathogenicity of SPG7 vari-
ants classified as variants of unknown significance (VUS),
while screening for the presence of additional candidate
variants in deep intronic regions. This screening will be
crucial to better determine the pathogenicity of SPG7
variants and improve current clinical management and
genetic counseling for these families.
Finally, the reported case is affected by cerebellar ataxia,
a frequent feature in SPG7-mutated patients (65–90%
patients),20,22,23 which was clearly predominant over the
spastic paraplegia component, and dysarthria (up to 76%
of patients in a recent cohort).23 Our patient only harbors
one heterozygous loss-of-function mutation (the deep
intronic cryptic splice variant), which is in line with his
predominantly ataxic phenotype, as a recent analysis of
249 patients associated biallelic loss-of-function mutations
in SPG7 with stronger spasticity phenotypes.20 This patient
also had PEO and a high degree of disability, which are
less common features in SPG7-mutated patients. PEO is
present in ~ 26% of Spanish patients, although frequency
doubles in patients not carrying the common p.Ala510Val
mutation in homozygosis.22,24 Given that SPG7 is one of
the most frequent causes of HSP, and also a relatively fre-
quent cause underlying hard-to-diagnose ataxias,25 it
would be prudent to search for intronic SPG7 variants in
patients with ataxia or spastic paraplegia, especially if they
have associated PEO, or are already known to harbor one
suspicious heterozygous variant in this gene.
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